2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

10. Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd
line gemcitabine and paclitaxel chemotherapy in patients with advanced
bladder cancer: short-term versus prolonged treatment [German Association
of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22:288-294.
11. Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as
second-line therapy in patients with metastatic urothelial carcinoma. Invest
New Drugs. 2007;25:265-270.
12. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel
in patients with advanced or metastatic transitional-cell carcinoma. J Clin
Oncol. 1997;15:1853-1857.
13. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of
pemetrexed for second-line treatment of transitional cell cancer of the
urothelium. J Clin Oncol. 2006;24:3451-3457.
14. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of
cisplatin-based and carboplatin-based chemotherapy for treatment of advanced
urothelial carcinoma. Ann Oncol. 2012;23:406-410.
15. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on
eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial
carcinoma of the bladder. Cancer. 2006;107:506-513.
16. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial
comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine
(M-CAVI) in patients (pts) with advanced urothelial cancer (UC)
unfit for cisplatin-based chemotherapy (CHT): phase III results of EORTC
study 30986. J Clin Oncol. 2010;28 (suppl; abstr LBA4519).
17. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with
metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin
Oncol. 2011;29:2432-2438.
18. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as
a novel prognostic marker in advanced bladder cancer patients receiving
cisplatin-based chemotherapy. Ann Oncol. 2007;18:522-528.
19. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression
signatures predict clinical outcomes of cancer patients undergoing
systemic therapy. Cancer Res. 2009;69:8302-8309.
20. Sjodahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene
mutations in urothelial carcinoma; inactivating mutations in TSC2 and
PIK3R1. PLoS One. 2011;6:e18583.
21. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter,
open-label phase 2 study of lapatinib as the second-line treatment of patients
308
MATTHEW D. GALSKY
with locally advanced or metastatic transitional cell carcinoma. Cancer.
2009;115:2881-2890.
22. Galsky MD, Von Hoff DD, Neubauer M, et al. Target-specific, histologyindependent,
randomized discontinuation study of lapatinib in patients with
HER2-amplified solid tumors. Invest New Drugs. Epub 2010 Sep 22.
23. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS,
NRAS and PIK3CA mutations in bladder cancer and their potential as
biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.
24. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin,
gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial
carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525-
1530.
25. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients
with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology
Group. Cancer. 2009;115:4090-4095.
26. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib
in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28:1373-
1379.
27. Galsky MD, Sonpavde G, Hellerstedt BA, et al. Phase II study of
gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial
carcinoma. Presented at the ASCO Genitourinary Oncology Symposium,
March 5-7, 2010, San Francisco, CA (abstr 276).
28. Choueiri T, Vaishampayan U, Yu EY, et al. A double-blind randomized
trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumpretreated
advanced urothelial cancer. Presented at the ASCO Genitourinary
Oncology Symposium, March 5-7, 2010, San Francisco, CA (abstr LBA239).
29. Krege S, Rexer H, vom Dorp F, et al. Gemcitabine and cisplatin with or
without sorafenib in urothelial carcinoma (AUO-AB 31/05). J Clin Oncol.
2010;28 (suppl; abstr 4574).
30. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes
are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl
Acad Sci USA.2007;104:3967-3972.
31. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade:
tolerability and immune monitoring in the setting of a presurgical clinical
trial. Clin Cancer Res. 2010;16:2861-2871.
32. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system
for cancer care. J Clin Oncol. 2010;28:4268-4274.